Idenix Pharmaceuticals (NASDAQ:IDIX) , which had its hepatitis C drugs put on clinical hold because it had a similar structure to Bristol-Myers Squibb’s BMS-986094, which had serious cardiac side effects. Idenix Pharmaceuticals Inc (NASDAQ:IDIX) stock performance was -6.45% in last session and finished the day at $7.11. Traded volume was 3,306,727 million shares in the last session and the average volume of the stock remained 1.48 million shares. The beta of the stock remained 0.08. Idenix Pharmaceuticals Inc (NASDAQ:IDIX) insider ownership is 25.11%.

OXiGENE Inc (NASDAQ:OXGN) on Mar. 18 reported financial results for the year ended December 31, 2013. For the year ended December 31, 2013, OXiGENE reported a net loss of $8.3 million compared to a net loss of $8.1 million for the comparable period in 2012. OXiGENE Inc (NASDAQ:OXGN) dropped -2.25 percent to $3.48 yesterday on volume of 4.04 million shares. The intra-day range of the stock was $3.47 to $3.99. OXiGENE Inc (NASDAQ:OXGN) has a market capitalization of $39.91 million.

Intrexon Corporation (NYSE:XON), a leader in synthetic biology, today announced that Samuel Broder, M.D., most recently Chairman of Intrexon’s Health Sector and former Director of the National Cancer Institute, has been named as Executive Vice President of Scientific and Public Affairs reporting to Chairman and Chief Executive Officer Randal J. Kirk. Intrexon Corp (NYSE:XON)’s stock on Mar 21, 2014 reported a decrease of -8.40% to the closing price of $28.14. Its fifty two weeks range is $17.52 -$38.50. The total market capitalization recorded $2.73 billion. The overall volume in the last trading session was 2,789,141 million shares. In its share capital, Intrexon Corp (NYSE:XON) has 54.31 million outstanding shares.

The most recent short interest data has been released by the NASDAQ for the 02/14/2014 settlement date, which shows a 372,586 share increase in total short interest for Enzon Pharmaceuticals Inc (NASDAQ:ENZN) to 1,161,223, an increase of 47.24% since 01/31/2014. On Friday, shares of Enzon Pharmaceuticals Inc (NASDAQ:ENZN) advanced 16.67% to close the day at $1.26. Company return on investment (ROI) is 0.10% and its monthly performance is recorded as 31.25%. Enzon Pharmaceuticals Inc (NASDAQ:ENZN) quarterly revenue growth is 12.50%.